stockrow
Saturday 7 November 2026
Export ATHE’s income statement to Excel — free account
Alterity Therapeutics Limited - Sponsored ADR
ATHE Healthcare Biotechnology
2.44
0.22
+9.91%
Follow ATHE
Alert me
Alterity Therapeutics Limited - Sponsored ADR (ATHE) P/E ratio
Alterity Therapeutics Limited - Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBIO iBio, Inc. compare | n/m |
| BMEA Biomea Fusion, Inc. compare | n/m |
| SGMOQ Sangamo Therapeutics, Inc. compare | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| CRBU Caribou Biosciences, Inc. compare | n/m |
| GANX Gain Therapeutics, Inc. compare | n/m |
| SER Serina Therapeutics, Inc. compare | n/m |
| ATNM Actinium Pharmaceuticals, Inc. compare | 3.9× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)